🇺🇸 FDA

Intelligence · Clinical Pipeline

Novartis India Pipeline

All ClinicalTrials.gov programs at Novartis India — phase, modality, and trial IDs.

Programs
121

Quick answer

Novartis India has 121 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. SODIUM CHLORIDE , DII235

    Novartis Pharmaceuticals

    Cardiovascular risk reduction in participants with elevated Lp(a)

    phase 2 small molecule active

    1 trial

  2. Scemblix 20 mg film-coated tablets, Tasigna 200 mg hard capsules, Scemblix 40 mg film-coated tablets, Tasigna 150 mg hard capsules

    Novartis Pharmaceuticals

    Chronic myeloid leukemia

    phase 2 small molecule active

    1 trial

  3. Scemblix 40 mg film-coated tablets

    Novartis Pharmaceuticals

    CML-CP or CML-AP patients with T315I mutation

    phase 2 small molecule active

    1 trial

  4. Scemblix 40 mg film-coated tablets, Scemblix 40 mg film-coated tablets, Scemblix 20 mg film-coated tablets, Scemblix 40 mg film-coated tablets, NILOTINIB, NILOTINIB, Scemblix 20 mg film-coated tablets, IMATINIB, IMATINIB

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response

    phase 2 small molecule active

    1 trial

  5. Seasonal flu vaccine

    Novartis Pharmaceuticals

    Seasonal Influenza

    phase 2 mab completed

    1 trial

  6. Serelaxin

    Novartis Pharmaceuticals

    Acute Heart Failure

    phase 2 small molecule completed

    1 trial

  7. TIN816, Placebo to TIN816 70mg powder for solution for injection or infusion

    Novartis Pharmaceuticals

    Acute kidney injury

    phase 2 small molecule active

    1 trial

  8. TIN816, Sterile 0.9% sodium chloride solution for infusion will be administered as placebo to participants randomized to the placebo treatment. The solution is ready to use in a 100mL infusion bag of 0.9% sodium chloride solution

    Novartis Pharmaceuticals

    Sepsis associated acute kidney injury

    phase 2 small molecule active

    1 trial

  9. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    Adult patients with refractory or relapsed follicular lymphoma

    phase 2 small molecule active

    1 trial

  10. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    High-risk B-cell acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  11. TNO155, JDQ443, TNO155, VDT482/ BGB-A317, JDQ443, TNO155, TNO155

    Novartis Pharmaceuticals

    Advance solid tumors harboring the KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  12. TOCILIZUMAB, FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE

    Novartis Pharmaceuticals

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  13. TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, LEE011, TEMOZOLOMIDE, TEMOZOLOMIDE

    Novartis Pharmaceuticals

    Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)

    phase 2 small molecule active

    1 trial

  14. VAY736, ARTICAINE, COMBINATIONS, TENOFOVIR ALAFENAMIDE, PERFLUTREN, PHOSPHOLIPID MICROSPHERES, ENTECAVIR , -

    Novartis Pharmaceuticals

    Sjögren's syndrome

    phase 2 small molecule active

    1 trial

  15. VAY736, Placebo Solution for injection or infusion 0 mg/1 mL

    Novartis Pharmaceuticals

    Moderate to severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  16. VAY736, TENOFOVIR ALAFENAMIDE, ENTECAVIR , -, VAY736, VAY736, TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Rheumatoid Arthritis, Sjögren’s Disease, Systemic Lupus erythematosus

    phase 2 small molecule active

    1 trial

  17. VHB937, Placebo 00 mg/ 00mL, concentrate for solution for infusion (Placebo to VHB937)

    Novartis Pharmaceuticals

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  18. Vi-CRM197 vaccine

    Novartis Pharmaceuticals

    Typhoid Fever

    phase 2 mab completed

    1 trial

  19. YTB323, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, TOCILIZUMAB

    Novartis Pharmaceuticals

    Non-active Progressive Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  20. YTB323, Flebogamma DIF 50 mg/ml solution for infusion, TOCILIZUMAB, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE

    Novartis Pharmaceuticals

    Treatment-resistant generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  21. alb-interferon alfa 2b

    Novartis Pharmaceuticals

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  22. cyclosporine (reduced exposure) / everolimus

    Novartis Pharmaceuticals

    Kidney Transplantation

    phase 2 small molecule completed

    1 trial

  23. eltrombopag

    Novartis Pharmaceuticals

    Thrombocytopaenia

    phase 2 small molecule completed

    1 trial

  24. rapcabtagene autoleucel

    Novartis Pharmaceuticals

    Scleroderma, Diffuse

    phase 2 mab active

    1 trial

  25. zigakibart

    Novartis Pharmaceuticals

    Immunoglobulin A Nephropathy (IgAN)

    phase 2 mab active

    1 trial

Frequently asked questions

How many pipeline programs does Novartis India have?

121 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.